Activated protein C: Potential therapy for severe sepsis, thrombosis, and stroke

Seminars in Hematology

Volumn 39, Issue 3, 2002, Pages 197-205

  Griffin, John H ^a,b   Zlokovic, Berislav ^a,b   Fernández, José A ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; PROTEIN C; THROMBIN;

ANTICOAGULANT THERAPY; DISEASE SEVERITY; DRUG ACTIVITY; HOMEOSTASIS; HUMAN; MORTALITY; PLASMA; PRIORITY JOURNAL; REVIEW; SEPSIS; STROKE; THROMBOSIS; TREATMENT PLANNING; CEREBROVASCULAR ACCIDENT; METABOLISM;

CEREBROVASCULAR ACCIDENT; HUMANS; PROTEIN C; SEPSIS; THROMBIN; THROMBOSIS;

EID: 0035992710     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.34093     Document Type: Article

References (79)

1. Protein C replacement in severe meningococcemia: Rationale and clinical experience
2. Effect of activated human protein C on experimental venous thrombosis induced by stasis with operative invasion in mice
3. Effect of activated human protein C on disseminated intravascular coagulation induced by lipopolysaccharide in rats
4. Inhibition of microarterial thrombosis by activated protein C in a rabbit model
5. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent
6. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C
7. Efficacy and safety of recombinant human activated protein C for severe sepsis
8. Changes in membrane phospholipid distribution during platelet activation
9. Inherited protein C deficiency and a coumarin-responsive chronic relapsing purpura fulminans syndrome in a neonate
10. Human protein C induces anticoagulation and increased fibrinolytic activity in the cat
11. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells
12. Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys
13. Generation of fibrinolytic activity by infusion of activated protein C into dogs
14. Thrombin signalling and protease-activated receptors
15. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway
16. Preclinical pharmacology of activated protein C
17. Inflammation and thrombosis. Mutual regulation by protein C
18. Dysfunction of endothelial protein C activation in severe meningococcal sepsis
19. Cardiolipin enhances protein C pathway anticoagulant activity
20. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C
21. 506-glutamine mutation
22. Prospective study of markers of hemostatic function with risk of ischemic stroke
23. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor
24. Characterization of protein C receptor expression in monocytes
25. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation
26. Deficiency of protein C in congenital thrombotic disease
27. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C
28. Direct detection of activated protein C in blood from human subjects
29. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model
30. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis
31. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates
32. Evaluation of activated protein C on canine infarct size in a nonthrombotic model of myocardial reperfusion injury
33. Activated protein C prevents endotoxin-induced hypotension in rabbits by inhibiting excessive production of nitric oxide
34. Preparation for trials of recombinant activated protein C in sepsis: A pharmacokinetic and dynamic study in healthy men and woman
35. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide
36. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis
37. Improvement of disseminated intravascular coagulation in severe sepsis patients treated with recombinant human activated protein C
38. Disseminated intravascular coagulation in severe sepsis patients treated with recombinant human activated protein C, a retrospective subgroup analysis from the PROWESS trial
39. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis
40. Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits
41. Comparison of hemorrhagic effect of heparin and human activated protein C with use of Thrombostan 4000
42. Enhancement of tissue plasminogene-activator-induced fibrinolysis by activated protein C in dotoxin-treated rabbits
43. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated inravascular coagulation
44. Patients with severe sepsis vary markedly in their ability to generate activated protein C
45. Impairments of the protein C system and fibrinolysis in infection-associated stroke
46. Brain-specific protein C activation during carotid artery occlusion in humans
47. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
48. Activated protein C reduces ischemia/repefusion-induced renal injury in rats by inhibiting leukocyte activation
49. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats
50. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production
51. Activated recombinant human protein C does not attenuate recruitment of neutrophils in rat models of acute inflammation
52. Regulation of inflammatory responses by natural anticoagulants
53. Treatment of patients with disseminated intravascular coagulation by protein C
54. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
55. Clinical impact of novel anticoagulation strategies in sepsis
56. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C
57. Cardiopulmonary bypass and activation of antithrombotic plasma protein C
58. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor
59. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits
60. Lipid oxidation enhances the function of activated protein C
61. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis
62. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn
63. Anti-inflammatory, antithrombotic and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke
64. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner
65. Platelet factor 4 (PF4) enhances generation of activated protein C in a primate model in vivo
66. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis
67. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C
68. Protein C activation following coronary artery occlusion in the in situ porcine heart
69. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex
70. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes
71. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon
72. Endothelial cell protein C receptor plays an important role in protein C activation in vivo
73. Effect of activated protein C on impaired fibrinolysis in rats with obstructive jaundice
74. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation
75. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial
76. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries
77. Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion in rat liver
78. Activated protein C versus protein C in severe sepsis
79. Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats